Dear Member,

As we move into Week 7 of our clinical series, we are addressing perhaps the most critical adherence barrier in cardiovascular medicine: The Secondary Prevention Paradox.

In both Coronary Heart Disease (CHD) and Acute Coronary Syndromes (ACS), patients often feel physically worseafter starting medication than they did before their diagnosis.

• The Paradox: The benefit (preventing a second heart attack/stent thrombosis) is invisible, while the side effects (fatigue, bruising, dyspnea) are visceral and immediate.
• The Result: Patients equate "feeling tired" with "damage," leading to non-adherence during the highest-risk window.

The "Secondary Prevention" Focus

This week, we are providing expert-level support sheets for:

Coronary Heart Disease (The "Cocktail" Fatigue): Patients starting Beta-blockers (e.g., Bisoprolol) often report "walking through treacle."

• The NMS Strategy: We reframe this fatigue not as a side effect, but as "Cardioprotection in Action." We explain that the drug is deliberately lowering the heart’s workload to preserve muscle function, and that energy levels typically recover within 4-6 weeks as the body adapts.

Acute Coronary Syndromes (Stent Anxiety): Post-ACS patients on potent DAPT (Ticagrelor/Prasugrel) experience dramatic bruising and occasionally "air hunger" (dyspnea).

• The NMS Strategy: We validate these sensations immediately. We explain that bruising is a "Visual Confirmation" that the blood is sufficiently thinned to pass through the new stent mesh safely. We also distinguish benign Ticagrelor-induced dyspnea from heart failure symptoms to prevent panic.

Why focus on these this week? The "Therapeutic Gap" here is fear. The patient stops because they fear the medication is weakening them. Your NMS intervention bridges this gap by turning "Side Effects" into "Signals of Efficacy."

Please review the attached guides and use them to structure your conversations to pre-empt these specific non-adherence triggers.

Mandatory Clinical Disclaimer: Pharmacists must always verify information against current sources. The materials provided in this series are visual training aids designed for educational purposes only. They should not be relied upon to make clinical decisions. Professional clinical judgement must be exercised at all times, and the latest SPC, BNF, and NICE guidelines must be consulted. The authors accept no liability for clinical errors.

Series Catch-Up: Previous Modules Sent to Date

To ensure your team has a complete clinical library, here is a recap of the high-impact modules we have covered in this series so far:

• Gout: Addressing the "Mobilization Flare" paradox—explaining why treatment triggers pain initially and the importance of prophylaxis.
• Type 2 Diabetes: Shifting from "Sugar Control" to "Organ Armour" and managing "Sick Day Rules" to prevent AKI.
• Glaucoma: Mastering "Punctal Occlusion" to prevent systemic side effects like bradycardia and bronchospasm.
• Urinary Incontinence: Managing the "Anticholinergic Gap"—where dry mouth hits immediately, but bladder control takes weeks.
• Lipid Management: Bridging the gap between "invisible" protection and the "Nocebo effect" of muscle pain.
• Osteoporosis: Engineering adherence for complex administration rules and preventing "The Silent Fracture.”
• Heart Failure: Focus on the "Initiation Titration" and monitoring for electrolyte imbalances with ACEi/Beta-Blockers.
• Epilepsy: Managing the "Bioequivalence" of different brands and the critical importance of a zero-miss dose policy.
• Parkinson’s: Engineering the "On/Off" phenomenon and the necessity of strict timing for Levodopa doses.
• Hypertension: Navigating the "Triple Whammy" (ACEi + Diuretic + NSAID) and managing the ACEi dry cough.
• Anticoagulation: Safety-netting for major bleeds and explaining the short half-life of DOACs compared to Warfarin.
• Depression: Bridging the "Suicide Window"—the dangerous period where physical energy returns before mood improves.

Regards,

PharmaPlus